Literature DB >> 320014

Plasma levels and half lives of thioridazine and some of its metabolites. I. High doses in young acute schizophrenics.

F A Vanderheeren, R G Muusze.   

Abstract

Plasma levels of thioridazine and four of its metabolites were determined in a series of fifteen young acute schizophrenics; Consistent individually different metabolic patterns were detected in a group of patients who had the same value for the sum of thioridazine plus metabolites. The apparent volume of distribution and half life were calculated. Clinical evolution tended to correlate best with the level of mesoridazine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 320014     DOI: 10.1007/bf00562905

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Plasma levels and clinical effects of thioridazine and thiothixene.

Authors:  R Bergling; T Mjorndal; L Oreland; W Rapp; S Wold
Journal:  J Clin Pharmacol       Date:  1975 Feb-Mar       Impact factor: 3.126

2.  THE EXCRETION AND METABOLISM OF 35S-LABELED THIORIDAZINE IN URINE, BLOOD, BILE, AND FECES.

Authors:  S EIDUSON; E GELLER
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

3.  Gas-liquid chromotographic determination of perazine, thioridazine and thioridazine metabolites in human plasma.

Authors:  F A Vanderheeren; D J Theunis
Journal:  J Chromatogr       Date:  1976-05-12

4.  Therapeutic effect and plasma level of thioridazine.

Authors:  F E de Jonghe; H J van der Helm; H F Schalken; J H Thiel
Journal:  Acta Psychiatr Scand       Date:  1973       Impact factor: 6.392

5.  Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug.

Authors:  S H Curry; G P Mould
Journal:  J Pharm Pharmacol       Date:  1969-10       Impact factor: 3.765

6.  Blood levels of thioridazine and some of its metabolites in psychiatric patients. A preliminary report.

Authors:  G Buyze; P F Egberts; R G Muusze; A Poslavsky
Journal:  Psychiatr Neurol Neurochir       Date:  1973 May-Jun

7.  Isolation of a possible new metabolite of thioridazine and mesoridazine from human plasma.

Authors:  E C Dinovo; L A Gottschalk; E P Noble; R Biener
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1974-03

8.  Quantitative determination of thioridazine and nonconjugated thioridazine metabolites in serum and urine of psychiatric patients.

Authors:  E Mårtensson; G Nyberg; R Axelsson; K Serck-Hansen
Journal:  Curr Ther Res Clin Exp       Date:  1975-11

9.  Serum concentration and elimination from serum of thioridazine in psychiatric patients.

Authors:  R Axelsson; E Mårtensson
Journal:  Curr Ther Res Clin Exp       Date:  1976-02

10.  [Therapeutic effect and plasma level of thioridazine in schizophrenic patients (author's transl)].

Authors:  H E Klein; O Chandra; N Matussek
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1975-05
View more
  8 in total

Review 1.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

3.  Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Kumanishi
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 4.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

5.  The disposition and elimination of stereoisomeric pairs of thioridazine 5-sulfoxide in the rat.

Authors:  P W Hale; S Melethil; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Oct-Dec       Impact factor: 2.441

6.  The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

Authors:  P W Hale; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

7.  Pediatric thioridazine poisoning as a result of a pharmacy compounding error.

Authors:  Zenichiro Kato; Mitsuhiro Nakamura; Yuka Yamagishi; Takahide Teramoto; Naomi Kondo
Journal:  Pediatr Rep       Date:  2009-06-08

8.  EAG2 potassium channel with evolutionarily conserved function as a brain tumor target.

Authors:  Xi Huang; Ye He; Adrian M Dubuc; Rintaro Hashizume; Wei Zhang; Jüri Reimand; Huanghe Yang; Tongfei A Wang; Samantha J Stehbens; Susan Younger; Suzanne Barshow; Sijun Zhu; Michael K Cooper; John Peacock; Vijay Ramaswamy; Livia Garzia; Xiaochong Wu; Marc Remke; Craig M Forester; Charles C Kim; William A Weiss; C David James; Marc A Shuman; Gary D Bader; Sabine Mueller; Michael D Taylor; Yuh Nung Jan; Lily Yeh Jan
Journal:  Nat Neurosci       Date:  2015-08-10       Impact factor: 24.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.